// Company Overview //
| Stock Name | 来凯医药－Ｂ |
|---|---|
| Stock Code | 02105 |
| Company Full Name | 来凯医药－Ｂ |
| Industry | 醫療保健 |
| Principal Activities | 公司成立于2016年，是一家以科學為驅動、處于臨床階段的生物醫藥科技公司。 |
| Listing Date | 2023-06-29 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市浦東新區張江高科技園區蔡倫路987號5樓 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | https://www.laekna.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Offering Mechanism | 未知 |
|---|---|
| Clawback Tiers | No data |
| Prospectus Date | 2023-06-16 |
| Offer Price | HK$ 12.41 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | — shares |
| Par Value | No data |
| Global Offering Shares | — |
| HK Public Offering Shares | — (0%) |
| International Placing Shares | — (0%) |
| Offer Ratio | No data |
| Total Shares Post-IPO | No data |
| Total Global Offering Size | HK$ — |
| Public Offering Size | HK$ — (0%) |
| Oversubscription Multiple | —x |
| Valid Applications | — |
| Accepted Applications | — |
| Reallocation | No |
| Total Funds Raised | HK$ 79,088,930 |
| Greenshoe (Over-allotment Option) | No data |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
|---|---|
| Pre-IPO Valuation (Last Round) | No data |
| P/E Ratio | -5.55 |
| Profit/Loss Status | No data |
| Period-End Cash Balance | No data |
| Listing Expenses | ~HK$ 82,700,000 |
| Listing Expenses / Funds Raised | No data |
| Total Pre-IPO Investment | No data |
// First Day Performance
| First Day Close | Loading... |
|---|---|
| First Day Open | HK$ 12.44 |
| First Day Change | 20.87% |
| First Day Volume | 2822000.0 |
| First Day Turnover | 39083600.0 |
// Price Chart //
Loading...
// Use of Proceeds
| Use of Proceeds | 1、約33.0%或約233.7百萬港元預計將用于迅速推進核心產品之一LAE001的臨床開發及批準； 2、約23.3%或約165.0百萬港元預計將用于推進本公司另一核心產品LAE002的臨床開發及批準； 3、約20.8%或147.4百萬港元預計將用于加快其他現有管線產品的研發，并不斷推進及改進我們的管線產品； 4、約9.9%或70.1百萬港元預計將用于提高產能及發展我們的制造能力； 5、約7.6%或53.8百萬港元預計將用于業務發展活動及增強全球網絡； 6、約5.4%或38.2百萬港元預計將用于營運資金及其他一般企業用途。 |
|---|
// Underwriting Syndicate //
独家保荐人 (1)
中国国际金融香港证券有限公司
整体协调人 (1)
中国国际金融香港证券有限公司
联席账簿管理人 (5)
中国国际金融香港证券有限公司
海通国际证券有限公司
工银国际证券有限公司
国泰君安证券（香港）有限公司
农银国际证券有限公司
联席牵头经办人 (7)
中国国际金融香港证券有限公司
海通国际证券有限公司
工银国际证券有限公司
国泰君安证券（香港）有限公司
农银国际证券有限公司
富途证券国际（香港）有限公司
华盛资本证券有限公司
// Cornerstone Investors //
Allotment Results Announcement
| # | Investor Name | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|
| 1 | 余姚陽明股權投資基金有限公司（「余姚」） 471,840,610港元 | 38,021,000 | 59.66% | 9.75% | — | — |
// Directors & Management //
| Chairman | 呂向陽 |
|---|---|
| Company Secretary | 柯晨煜 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | OrbiMed Asia Partners III, L.P.(14.84%);呂向陽(12.72%);GP實體(10.49%);ESOP信托(8.75%);北京安龍實體(5.78%) |
|---|
// Allotment Benchmarks //
Pool A (Small Subscriptions)
| Shares Applied | Applicants | Allottees | Expected Lots |
|---|---|---|---|
| 500 | 1,636 | 365 | — |
| 1,000 | 199 | 88 | — |
| 1,500 | 84 | 55 | — |
| 2,000 | 67 | 58 | — |
| 2,500 | 48 | 3 | — |
| 3,000 | 32 | 8 | — |
| 3,500 | 149 | 68 | — |
| 4,000 | 20 | 13 | — |
| 4,500 | 6 | 5 | — |
| 5,000 | 47 | 1 | — |
| 6,000 | 8 | 3 | — |
| 7,000 | 43 | 33 | — |
| 8,000 | 18 | 2 | — |
| 9,000 | 5 | 2 | — |
| 10,000 | 35 | 21 | — |
| 15,000 | 52 | 16 | — |
| 20,000 | 22 | 1 | — |
| 25,000 | 6 | 4 | — |
| 30,000 | 6 | 2 | — |
| 35,000 | 2 | 2 | — |
| 40,000 | 3 | 2 | — |
| 45,000 | 3 | 1 | — |
| 50,000 | 6 | 6 | — |
| 60,000 | 4 | 1 | — |
| 70,000 | 1 | 1 | — |
| 80,000 | 9 | 2 | — |
| 100,000 | 14 | 11 | — |
| 200,000 | 5 | 2 | — |
| 300,000 | 8 | 1 | — |
| 400,000 | 18 | 14 | — |
Pool B (Large Subscriptions)
| Shares Applied | Applicants | Allottees | Expected Lots |
|---|---|---|---|
| 500,000 | 5 | 5 | — |
| 700,000 | 2 | 2 | — |
| 800,000 | 2 | 2 | — |
| 1,000,000 | 1 | 1 | — |
| 2,500,000 | 1 | 1 | — |
| 3,186,500 | 3 | 3 | — |
Allotment Benchmarks
